Brown & Brown, Inc. (BRO) reported first‑quarter 2026 results that highlighted a 35.4% year‑over‑year revenue increase to $1.901 billion, driven almost entirely by the $9.825 billion Accession acquisition completed on August 1, 2025. The acquisition added a new Specialty Distribution unit and expanded the company’s footprint, accounting for the bulk of the headline growth.
The company’s diluted net income per share was $1.06, while adjusted earnings per share rose to $1.39. Adjusted EPS beat the consensus estimate of $1.36 by $0.03, a 2.2% beat, reflecting disciplined cost management and a favorable mix of high‑margin specialty distribution contracts. GAAP EPS of $1.06 fell short of the prior‑year quarter’s $1.15, underscoring the impact of flat organic revenue and integration costs.
Total revenue rose 35.4% from $1.4 billion in Q1 2025, but organic revenue was flat at 0.0% growth, with a 2.2% increase when contingent commission revenue is included. The Retail segment posted 1.0%–1.3% organic growth, while the new Specialty Distribution unit experienced a decline due to prior‑year flood‑claim revenue. Headwinds such as declining catastrophe property rates, litigation‑related customer losses, and a transition in specialty pharmacy consulting operations further dampened organic momentum.
Management reiterated its 2026 guidance, maintaining a modest outlook for organic growth while emphasizing the continued integration of Accession’s operations. CEO J. Powell Brown noted that “our teammates continue to deliver for our customers in a challenging growth environment,” and highlighted ongoing investments in technology and AI to enhance customer experience and operational efficiency.
Investors focused on the contrast between the strong acquisition‑driven revenue growth and the flat organic performance. The adjusted EPS beat and margin expansion were viewed positively, while the flat GAAP EPS and lack of organic growth raised concerns about the sustainability of the company’s core business. The market reaction reflected this mixed assessment, with analysts weighing the benefits of the Accession deal against the challenges of translating the transaction into long‑term organic growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.